Meissa's Positive Interim Clinical Data for Its Intranasal Live Attenuated RSV Vaccine for Infants

Meissa Vaccines Presented at The White House Summit on the Future of COVID-19 Vaccines

Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

Meissa Appoints Drs. Dan H. Barouch and Mark J. Mulligan to Scientific Advisory Board

Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID

Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose

Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

Meissa Vaccines Appoints Dr. Michael Watson to Board of Directors

Meissa Announces IND Clearance for Phase 1 Study of COVID-19 Intranasal Live Attenuated Vaccine

Meissa Announces 1st Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Candidates

Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine

Meissa Vaccines Closes $30 Million Financing to Advance RSV Vaccine into Clinical Trials

Meissa Vaccines Closes $3.4 Million Financing to Advance RSV Vaccine to Clinic

Meissa Vaccines Announces Seed Round Investment from FundRx

Meissa Vaccines Awarded NIH SBIR Grant to Advance IND Preparations for RSV Vaccine Candidate

Meissa Vaccines Receives FDA Clearance of IND Application, Phase 1 Clinical Trial of MV-012-968

Meissa Awarded NIH SBIR Grant to Support Development of Multivalent Human Rhinovirus Vaccine Candida